CLL Is Associated with Development of Subclinical Cytomegalovirus Viraemia and Accumulation of Large Populations of “exhausted” CMV-Specific CD4+ T Cells
Helen M Parry , Natasha Cutmore , Nikhil Mirajkar , Annette Pachnio
Blood 124 ( 21) 3290 -3290
2014
Subcutaneous PAD As Induction Therapy for Patients with Newly Diagnosed Myeloma: A Phase 2 Trial Assessing the Impact of Minimal Residual Disease (MRD) in Patients with Deferred Autologous Stem Cell Transplantation (PADIMAC)
Rakesh Popat , James D Cavenagh , Roger G Owen , Matthew Streetly
Blood 124 ( 21) 4745 -4745
1
2014
Evaluation of serum markers in the LRF CLL4 trial: β2-microglobulin but not serum free light chains, is an independent marker of overall survival
Guy Pratt , Peter Thomas , Nicola Marden , Denis Alexander
Leukemia & Lymphoma 57 ( 10) 2342 -2350
4
2016
Bezafibrate and medroxyprogesterone acetate target resting and CD40L-stimulated primary marginal zone lymphoma and show promise in indolent B-cell non-Hodgkin lymphomas
Rachel E. Hayden , Racha Kussaibati , Laura M. Cronin , Guy Pratt
Leukemia & Lymphoma 56 ( 4) 1079 -1087
2
2015
The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial
Gordon Cook , A John Ashcroft , David A Cairns , Cathy D Williams
The Lancet Haematology 3 ( 7)
61
2016
Panobinostat plus bortezomib and dexamethasone for relapsed myeloma.
Guy Pratt
The Lancet Haematology 3 ( 11)
1
2016
Therapy With Steroid-Containing Regimens in Myeloma Patients Can Result in Significantly Low Serum Cortisol Levels
Mark Cook , Guy Pratt , Rebecca Powell , Andrew Toogood
Clinical Lymphoma, Myeloma & Leukemia 19 ( 10)
2019
Outcomes of newly diagnosed multiple myeloma with deferred ASCT after achieving ≥VGPR following PAD induction in the Phase 2 PADIMAC study
Wei Yee Chan , Nicholas Counsell , Rakesh Popat , Ruth De Tute
Clinical Lymphoma, Myeloma & Leukemia 19 ( 10)
2019
Minimal residual disease (MRD) in Waldenström macroglobulinaemia (WM): Impact on survival outcomes with rituximab-based therapies.
Ruth De Tute , Andrew Rawstron , Shirley D'Sa , Guy Pratt
Clinical Lymphoma, Myeloma & Leukemia 19 ( 10)
2019
Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk
Angel Carracedo , Jesper Jurlander , Elias Campo , Gunnar Juliusson
Nature Genetics 42 ( 2) 132 -136
198
2010
Inhibition of Histone Deacetylase Activity Compromises Homologous Recombination Repair and Increases Sensitivity of Chemo-Resistant Chronic Lymphocytic Leukemia Cells to Olaparib
Angelo Agathanggelou , David Cartwright , Helen Parry , Guy Pratt
Blood 120 ( 21) 3891 -3891
2012
Diagnostic pathways in multiple myeloma and their relationship to end organ damage: an analysis from the Tackling Early Morbidity and Mortality in Myeloma (TEAMM) trial.
Catherine Atkin , Gulnaz Iqbal , Tim Planche , Guy Pratt
British Journal of Haematology 192 ( 6) 997 -1005
2021
Janus kinase 2 (JAK2) inhibitors in the treatment of multiple myeloma: modulating the myeloma immune microenvironment
Hannah Giles , Guy Pratt
British Journal of Haematology 192 ( 3) 420 -422
2021
Red cell transfusion in outpatients with myelodysplastic syndromes: a feasibility and exploratory randomised trial
Simon J. Stanworth , Sally Killick , Zoe K. McQuilten , Marina Karakantza
British Journal of Haematology 189 ( 2) 279 -290
44
2020
Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with multiple myeloma receiving systemic anti-cancer therapy.
Gordon Cook , A John Ashcroft , Guy Pratt , Rakesh Popat
British Journal of Haematology 190 ( 2)
37
2020
Polyclonal Serum FLC Levels: a Simple Risk Stratification Model for Identifying Aggressive Stage A CLL.
Guy Pratt , Alison Levoguer , Jeffrey Faint , Chris Fegan
Blood 116 ( 21) 4608 -4608
2010
The interleukin-6 receptor alpha-chain (CD126) is expressed by neoplastic but not normal plasma cells.
Andy C. Rawstron , James A. L. Fenton , John Ashcroft , Anne English
Blood 96 ( 12) 3880 -3886
69
2000
New Therapeutic Strategy for Sensitisation of CLL Cells with Inactivation of the DNA Damage Response by Targeting the Deubiquitylating Enzyme USP7-Dependent Pathways,
Angelo Agathanggelou , Anastasia Zlatanou , Ahmed Gulshanara , Grant Stewart
Blood 118 ( 21) 3865 -3865
2011
Elevated Chemokine Expression in the Bone Marrow of Patients with Myeloma and MGUS Is Associated with Marked Alterations in the Distribution of CD4+ and CD8+ T Cell Subsets within the Blood and Bone Marrow
Oliver Goodyear , Sarah Essex , Helen McGettrick , Supratik Basu
Blood 118 ( 21) 5076 -5076
2011
R2W: Subcutaneous Bortezomib, Cyclophosphamide and Rituximab (BCR) Versus Fludarabine, Cyclophosphamide and Rituximab (FCR) for Initial Therapy of WaldenstrőM's Macroglobulinemia: A Randomised Phase II Study
Rebecca L Auer , Roger G Owen , Shirley D'Sa , Guy Pratt
Blood 128 ( 22) 618 -618
9
2016